Cell fusion could be a potential therapeutic strategy to treat retinal damage

Fusing human retinal cells with adult stem cells could be a potential therapeutic strategy to treat retinal damage and visual impairment, according to the findings of a new study published in the journal eBioMedicine. The hybrid cells act by awakening the regenerative potential of human retinal tissue, previously only thought to be the preserve of cold-blood vertebrates.

Cell fusion events – the combination of two different cells into one single entity – are known to be a possible mechanism contributing to tissue regeneration. Though rare in humans, the phenomenon has been consistently detected in the liver, brain, and gastrointestinal tract.

A team led by ICREA Research Professor Pia Cosma at the Centre for Genomic Regulation (CRG) in Barcelona and funded by Fundació "la Caixa" has now found that cell fusion events also take place in the human retina.

The researchers tested whether cell fusion events could differentiate into cells that turn into neurons, which would show potential for tissue regeneration. The team fused Müller glia, cells that play a secondary but important role in maintaining the structure and function of the retina, with adult stem cells derived from human adipose tissue or bone marrow.

We were able to carry out cell fusion in vitro, creating hybrid cells. Importantly, the process was more efficient in the presence of a chemical signal transmitted from the retina in response to damage, resulting in rates of hybridization increasing twofold. This gave us an important clue for the role of cell fusion in the retina."

Sergi Bonilla, postdoctoral researcher at the CRG and first author of the study

The hybrid cells were injected into a growing retinal organoid, a model that closely resembles the function of the human retina. The researchers found that the hybrid cells successfully engrafted into the tissue and differentiated into cells that closely resemble ganglion cells, a type of neuron essential for vision.

"Our findings are important because they show that the Müller Glia in the human retina have the potential to regenerate neurons," says Pia Cosma. "Salamanders and fish can repair damage caused to the retina thanks to their Müller glia, which differentiate into neurons that rescue or replace damaged neurons. Mammalian Müller glia have lost this regenerative capacity, which means retinal damage or degradation can lead to visual impairment for life. Our findings bring us one step closer to recovering this ability."

The authors caution that much work remains to be done before the development of any potential treatments. One of the next steps is understanding why hybrid cells – with four complete sets of chromosomes – don't result in chromosomal instability and cancer development. The authors of the study believe the retina may have a mechanism regulating chromosome segregation similar to the liver, which contains tetraploid cells that act as a genetic reservoir, undergoing mitosis in response to stress and injury.

The study was led by the Centre for Genomic Regulation in collaboration with the Institute for Bioengineering of Catalonia (IBEC) and the Barraquer Ophthalmology Center. The work is mainly funded by the CaixaResearch Health Research Call from Fundació "la Caixa" awarded to Pia Cosma (CRG), Nuria Montserrat (IBEC) and Justin Christopher D'Antin (Barrraquer). It is also funded by the European Union's FET-Open EcaBox project, Velux Stiftung, the Spanish Ministry of Science and Innovation and the Catalan Agency for Management of University and Research (AGAUR).

Source:
Journal reference:

Bonilla-Pons, S.A., et al. (2022) Müller glia fused with adult stem cells undergo neural differentiation in human retinal models. eBioMedicine. doi.org/10.1016/j.ebiom.2022.103914.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MaxCyte celebrates 25 years of innovation driving cell engineering-based therapeutics